Cargando…

Fampridine and quality of life in individuals with multiple sclerosis

BACKGROUND: Fampridine improves walking in patients with multiple sclerosis (pwMS). However, little is known about its impact on the quality of life (QoL) of pwMS. OBJECTIVES: This study aimed to evaluate the contribution of fampridine on the QoL of pwMS and to determine if improvements in QoL are b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sagawa, Yoshimasa, Magnin, Eloi, Paillot, Laura, Moulin, Thierry, Decavel, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943908/ https://www.ncbi.nlm.nih.gov/pubmed/27462518 http://dx.doi.org/10.1186/s40064-016-2776-2

Ejemplares similares

Physical Activity during Weekdays and Weekends in Persons with Multiple Sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2021)

Locomotor Strategy to Perform 6-Minute Walk Test in People with Multiple Sclerosis: A Prospective Observational Study
por: Hadouiri, Nawale, et al.
Publicado: (2023)

Evaluation of Prolonged Walking in Persons with Multiple Sclerosis: Reliability of the Spatio-Temporal Walking Variables during the 6-Minute Walk Test
por: Hadouiri, Nawale, et al.
Publicado: (2021)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
por: Kanhai, Kawita M. S., et al.
Publicado: (2019)

Medical teachers’ opinions about students with neurodevelopmental disorders and their management
por: Magnin, Eloi, et al.
Publicado: (2021)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Modification of both functional neurological symptoms and neuroimaging patterns with a good anatomoclinical concordance: a case report
por: Galli, Silvio, et al.
Publicado: (2019)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

An fMRI study on the influence of sommeliers' expertise on the integration of flavor
por: Pazart, Lionel, et al.
Publicado: (2014)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Quality of Life in Multiple Sclerosis
por: Williams, Mitchell T., et al.
Publicado: (2020)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
por: Brochet, Bruno, et al.
Publicado: (2022)

Predicting Acute Ischaemic Stroke Outcome Using Clinical and Temporal Thresholds
por: Sablot, Denis, et al.
Publicado: (2011)

Methodological Investigation of Time Perspective Scoring and Quality of Life among Individuals with Multiple Sclerosis
por: Carl, Ellen, et al.
Publicado: (2022)

Discriminative ability of quality of life measures in multiple sclerosis
por: Fiest, Kirsten M., et al.
Publicado: (2017)

Voice-Related Quality of Life in Patients with Multiple Sclerosis
por: Hamdan, Abdul Latif, et al.
Publicado: (2012)

Progressive multiple sclerosis, cognitive function, and quality of life
por: Højsgaard Chow, Helene, et al.
Publicado: (2018)

Contributing Factors to the Quality of Life in Multiple Sclerosis
por: Sehanovic, Aida, et al.
Publicado: (2020)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
por: Simone, Isabella Laura, et al.
Publicado: (2006)

Individual quality of life in patients with multiple myeloma
por: Dürner, Julia, et al.
Publicado: (2013)

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases
por: Prugger, Michael, et al.
Publicado: (2013)

Social Characteristics and Quality of Life of Portuguese Multiple Sclerosis Patients
por: Costa, David Castro, et al.
Publicado: (2013)

The impact of quality of life on treatment preferences in multiple sclerosis patients
por: Lee Mortensen, Gitte, et al.
Publicado: (2017)

Contributing factors to health‐related quality of life in multiple sclerosis
por: Biernacki, Tamás, et al.
Publicado: (2019)

Biopsychosocial Correlates of Quality of Life in Multiple Sclerosis Patients
por: Batista, Ana Rita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5vgr025cdikh84ad1h92v81sc1